REGENXBIO Inc. Quarterly Operating Income (Loss) in USD from Q3 2014 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
REGENXBIO Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q3 2014 to Q2 2024.
  • REGENXBIO Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$56M, a 23.4% increase year-over-year.
  • REGENXBIO Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$249M, a 7.21% increase year-over-year.
  • REGENXBIO Inc. annual Operating Income (Loss) for 2023 was -$268M, a 2% decline from 2022.
  • REGENXBIO Inc. annual Operating Income (Loss) for 2022 was -$263M, a 264% decline from 2021.
  • REGENXBIO Inc. annual Operating Income (Loss) for 2021 was $160M.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$249M -$56M +$17.1M +23.4% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-01
Q1 2024 -$266M -$63.9M +$2.29M +3.47% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 -$268M -$63.9M -$6.13M -10.6% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-27
Q3 2023 -$262M -$65M +$6.09M +8.57% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-08
Q2 2023 -$268M -$73.1M -$10.6M -16.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 -$258M -$66.2M +$5.37M +7.51% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 -$263M -$57.8M -$371M -118% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-27
Q3 2022 $108M -$71M -$13.7M -23.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $122M -$62.5M -$10.3M -19.7% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 $132M -$71.5M -$27.5M -62.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-03
Q4 2021 $160M $314M +$367M Oct 1, 2021 Dec 31, 2021 10-K 2024-02-27
Q3 2021 -$207M -$57.3M -$71.3M -511% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$136M -$52.2M -$10.4M -24.8% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-03
Q1 2021 -$126M -$44M -$6.34M -16.8% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 -$119M -$53.7M -$13.3M -33.1% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-28
Q3 2020 -$106M $14M +$49.8M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-02
Q2 2020 -$156M -$41.8M -$4.96M -13.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 -$151M -$37.7M -$1.79M -5% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 -$149M -$40.3M -$42.8M -1746% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-01
Q3 2019 -$106M -$35.9M -$13.2M -58% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-04
Q2 2019 -$93.1M -$36.9M -$43.2M -681% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 -$49.8M -$35.9M -$138M -135% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 $88.1M $2.45M +$19M Oct 1, 2018 Dec 31, 2018 10-K 2021-03-01
Q3 2018 $69.1M -$22.7M -$1.42M -6.65% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-05
Q2 2018 $70.5M $6.35M +$21.4M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 $49.1M $102M +$125M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-07
Q4 2017 -$75.9M -$16.6M +$3.87M +18.9% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-26
Q3 2017 -$79.8M -$21.3M -$2.64M -14.1% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-07
Q2 2017 -$77.1M -$15.1M -$104K -0.7% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-08
Q1 2017 -$77M -$22.9M -$11.7M -104% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-08
Q4 2016 -$65.3M -$20.5M -$15M -272% Oct 1, 2016 Dec 31, 2016 10-K 2019-02-27
Q3 2016 -$50.4M -$18.7M -$11.3M -154% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-08
Q2 2016 -$39.1M -$15M -$8.66M -137% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-08
Q1 2016 -$30.4M -$11.3M -$7.26M -182% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-09
Q4 2015 -$23.1M -$5.5M Oct 1, 2015 Dec 31, 2015 10-K 2018-03-06
Q3 2015 -$7.35M -$5.65M -332% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-09
Q2 2015 -$6.3M Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-09
Q1 2015 -$3.99M Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-05
Q3 2014 -$1.7M Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-05
* An asterisk sign (*) next to the value indicates that the value is likely invalid.